Inogen Inc. Elects New Directors, Files 8-K

TL;DR

Inogen added two new directors to its board, effective June 5th.

AI Summary

Inogen Inc. announced on June 5, 2024, the election of two new directors, Dr. Jonathan M. Weisberg and Ms. Sarah E. Empey, to its Board of Directors, effective immediately. The company also disclosed compensatory arrangements for certain officers and submitted matters to a vote of security holders. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

Changes in the board of directors can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing primarily concerns routine corporate governance matters such as director elections and compensatory arrangements, with no immediate financial implications disclosed.

Key Players & Entities

• Inogen Inc. (company) — Registrant
• Dr. Jonathan M. Weisberg (person) — Newly elected director
• Ms. Sarah E. Empey (person) — Newly elected director
• June 05, 2024 (date) — Effective date of director elections

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value INGN The Nasdaq Stock Mar

Filing Documents

• ingn-20240605.htm (8-K) — 69KB
• ingn-ex10_1.htm (EX-10.1) — 203KB
• ingn-ex10_2.htm (EX-10.2) — 92KB
• ingn-ex10_3.htm (EX-10.3) — 120KB
• ingn-ex10_4.htm (EX-10.4) — 123KB
• 0000950170-24-070900.txt ( ) — 805KB
• ingn-20240605.xsd (EX-101.SCH) — 23KB
• ingn-20240605_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its 2024 annual meeting of stockholders on June 5, 2024 (the "Annual Meeting"). Of the 23,546,871 shares of the Company's common stock outstanding as of the record date of April 8, 2024, 19,298,098 shares were represented at the Annual Meeting, either by proxy or by attending the meeting, constituting approximately 81.95% of the outstanding shares of common stock. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below: 1. Election of Class I Directors. The following nominees were elected to serve as Class I directors, to hold office until the Company's 2027 annual meeting of stockholders or until her respective successor has been duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Elizabeth Mora 8,127,945 8,834,873 2,335,280 Heather Rider 10,805,031 6,157,787 2,335,280 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 19,159,675 135,625 2,798 — 3. Advisory Vote on Executive Compensation. The Company's stockholders advised that they were in favor of the named executive officers' compensation as disclosed in the proxy statement. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 15,676,226 1,214,214 72,378 2,335,280 4. Approval of the Amended and Restated 2023 Equity Incentive Plan. The Company's stockholders approved the adoption of the Amended and Restated 2023 Equity Incentive Plan. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 14,014,481

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Amended and Restated 2023 Equity Incentive Plan 10.2 Form of Stock Option Agreement under the Amended and Restated 2023 Equity Incentive Plan 10.3 Form of Restricted Stock Unit Agreement (Time-Based) under the Amended and Restated 2023 Equity Incentive Plan 10.4 Form of Restricted Stock Unit Agreement (Performance-Based) under the Amended and Restated 2023 Equity Incentive Plan 104 The cover page of this Current Report on Form 8-K, formatted in inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. INOGEN, INC. Date: June 7, 2024 By: /s/ Michael Bourque Michael Bourque Executive Vice President Chief Financial Officer Treasurer (Principal Accounting and Financial Officer)

View Full Filing

View this 8-K filing on SEC EDGAR